Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment

Abstract The aim of this study was to evaluate the impact of renal impairment on the pharmacokinetics (PKs), safety, and tolerability of daridorexant, a dual orexin receptor antagonist intended for the treatment of insomnia. A single‐center, open‐label study evaluated the PKs of daridorexant in pati...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Benjamin Berger, Clemens Muehlan, Gernot Klein, Jasper Dingemanse
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/fc8b4cfe396c4a1ebd06e4c57683c6a4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!